From October 9th to 11th, 2020, the "Tianfu Talking·CHS 2020 5th China Health Industry Upgrading Summit" was grandly held in Chengdu. With the theme of "Distributed Innovation · Reconstruction of a Healthy Ecology", this summit took the form of 1 main venue + 4 sub-forums + several supporting activities, focusing on five themes of innovative medicines, smart medical care, non-public medical care, health management, and health big data applications, gather hundreds of medical professionals from all walks of life, including politics, industry, education, research, and investment to discuss the innovation of the big health industry.
As an important part of this summit, the "Health Management Industry Forum" was held on the afternoon of October 11. According to the latest statistics from the National Health Commission, China has nearly 300 million people with chronic diseases, an increase of 10 million people every year, China has entered a period of high incidence of chronic diseases, and it also has the world's largest group of patients with chronic diseases. Chronic disease management has become a topic that must be discussed in health management. From the perspective of the industry, Jianmin Gan, Chairman of Minkang Biotechnology, delivered a keynote speech entitled "New Trends in Chronic Disease Management and Product R&D", revealing the new development trend of the chronic disease management industry.
Chairman Gan Jianmin believes that the further deepening of the hierarchical diagnosis and treatment model is an important beginning from the "13th Five-Year Plan" period to the "14th Five-Year Plan", because diagnosis and treatment may make important changes to chronic disease management. Chronic disease (non-communicable disease) management products should not only be limited to blood lipids, blood glucose, blood pressure, weight, etc., but also need to pay attention to blood ketone testing, uric acid testing, glycosylated hemoglobin (HbA1c) testing, urine microalbumin (kidney) Function) testing, continuous blood glucose meter, and cardiovascular and cerebrovascular monitoring related product development trends. At present, the detection of chronic disease indicators is gradually collecting blood glucose through detection data, and then developing to intelligent data transmission.
On the evening of October 10th, at the awards banquet of the “Tianfu Talking CHS 2020 Fifth China Health Industry Upgrading Summit”, the list of “Influence of China's Health Industry in 2020” selected by Yiou Think Tank was announced. The list takes as its mission to find the most innovative and energetic big health figures, enterprises, investment institutions and parks in China, integrate new technologies, new policies, and new concepts into the big health industry, and tap the core forces in the process of medical innovation.
In the current stimulus of the new crown epidemic, the pace of innovation in the big health industry is rapidly advancing, and the diversified components of the big health ecology have begun to reorganize and upgrade. Driven by new technologies and new models, the big health industry has become more innovative. Imagine more space, and a number of innovative companies with the characteristics of the times have emerged. Minkang Biotechnology was listed in the "2020 China Health Industry Innovation Award Best Health Management Innovation Enterprise" list. Chairman Gan Jianmin attended the awards dinner and delivered speeches on the award.
